Compound comparison
Maridebart cafraglutide vs Retatrutide
This page sets Maridebart cafraglutide and Retatrutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.
Side-by-side comparison
- Class
- Maridebart cafraglutidePeptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activityRetatrutideTriple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
- Mechanism
- Maridebart cafraglutideIn plain terms, maridebart cafraglutide is a lab-built molecule that turns on the GLP-1 receptor to reduce appetite while blocking a second gut-hormone receptor called GIP, attached to an antibody scaffold that keeps it in the body long enough for once-monthly dosing.RetatrutideIn plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy.
- United States (FDA)
- Maridebart cafraglutideNot approved. Investigational only; in clinical development for obesity and type 2 diabetes and not authorized for any indication.RetatrutideInvestigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025.
- European Union (EMA)
- Maridebart cafraglutideNot authorized. Investigational; no EU marketing authorisation.RetatrutideNot authorized; investigational, no marketing authorization.
- Australia (TGA)
- Maridebart cafraglutideNot registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.RetatrutideNot entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
- WADA
- Maridebart cafraglutideNot listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).RetatrutideNot listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited.
- Evidence grade
- Maridebart cafraglutideBRetatrutideB
- Tracked clinical trials
- Maridebart cafraglutide24Retatrutide34
- Full profile
- Maridebart cafraglutideRetatrutide
| Attribute | Maridebart cafraglutide | Retatrutide |
|---|---|---|
| Class | Peptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activity | Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide) |
| Mechanism | In plain terms, maridebart cafraglutide is a lab-built molecule that turns on the GLP-1 receptor to reduce appetite while blocking a second gut-hormone receptor called GIP, attached to an antibody scaffold that keeps it in the body long enough for once-monthly dosing. | In plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy. |
| United States (FDA) | Not approved. Investigational only; in clinical development for obesity and type 2 diabetes and not authorized for any indication. | Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025. |
| European Union (EMA) | Not authorized. Investigational; no EU marketing authorisation. | Not authorized; investigational, no marketing authorization. |
| Australia (TGA) | Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia. | Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply. |
| WADA | Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide). | Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited. |
| Evidence grade | B | B |
| Tracked clinical trials | 24 | 34 |
| Full profile | Maridebart cafraglutide profile | Retatrutide profile |
Common questions
- What is the difference between Maridebart cafraglutide and Retatrutide?
- Maridebart cafraglutide is classified as: Peptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activity. Retatrutide is classified as: Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide). Maridebart cafraglutide is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine.
- Is Maridebart cafraglutide or Retatrutide approved?
- Maridebart cafraglutide is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
- How much clinical trial evidence is tracked for Maridebart cafraglutide and Retatrutide?
- Peptide Science Daily tracks 24 registered clinical trials for Maridebart cafraglutide (evidence grade B) and 34 for Retatrutide (evidence grade B).